This article is more than 5 years old. Information may no longer be current.
EUCLID trial will compare ticagrelor vs. clopidogrel in PAD patients
AstraZeneca announced the initiation of the EUCLID study, a global clinical trial involving 11,500 patients with peripheral artery disease assigned ticagrelor or clopidogrel.
The Examining Use of Ticagrelor in PAD (EUCLID) study is designed to evaluate CV event rate and safety associated with the two drugs.
Ticagrelor (Brilinta, AstraZeneca) is FDA approved to reduce the rate of thrombotic CV events in patients with acute coronary syndromes. It is not currently approved for the treatment of patients with PAD.
The randomized, double blind, parallel-group, multicenter trial will include symptomatic PAD patients aged 50 years and older. Participants will be randomly assigned to twice-daily ticagrelor 90 mg or clopidogrel 75 mg. The primary endpoint is the composite of CV death, MI or ischemic stroke.
“The EUCLID study is an exciting clinical trial, as it may provide further clinical evidence regarding the role oral antiplatelets can play in reducing risk for patients with PAD,” principal investigator William Hiatt, MD, from University of Colorado School of Medicine, stated in a press release.
EUCLID is being conducted in partnership with the Duke Clinical Research Institute and CPC Clinical Research, an academic research organization affiliate of University of Colorado.